
Amylou Dueck, PhD
@biostatgirl
Statistical superhero. Professional data whisperer. Hall of fame golfer. And lover of bar charts (#sorrynotsorry). Tweets are my own.
ID: 223630281
06-12-2010 22:33:53
825 Tweet
715 Takipçi
230 Takip Edilen


Implementation of Symptom Monitoring With Electronic Patient-Reported Outcomes: Perspectives and Recommendations From Community Oncology Practices (Alliance AFT-39). ascopubs.org/doi/10.1200/OP… ASCO Journal of Clinical Oncology JCO Oncology Practice #PallOnc #CancerCare Alliance for Clinical Trials in Oncology Ethan Basch Amylou Dueck, PhD


An excellent #SuppOnc article re: #ePRO #ePRO can: ⬆️ communication 🗣️ 🤕symptom awareness 🧑💻 self-management. 🚧 Barriers exist. Needs better integration 💻, training,🎓 and actionable #pallonc content ✅ 🔗: ascopubs.org/doi/10.1200/OP… Ethan Basch Amylou Dueck, PhD OncoAlert🚨


Hats off to Dr. Sumithra Mandrekar Mayo Clinic - recipient of the 2025 Charles Moertel Lecture Award. Her lecture's entitled "Harnessing Alliance Clinical Trials Data to Drive Efficiency and Innovation in Cancer Trials Conduct and Research." #AlliancePlenary25 #GroupStatistician


Remote Symptom Monitoring With Electronic Patient-Reported Outcomes in Clinical #Cancer Populations. jamanetwork.com/journals/jaman… JAMA JAMA Network JAMA Network Open #PallOnc #SuppOnc #CancerResearch


Presenting a #patientreportedoutcomes workshop at Society for Clinical Trials 46th Annual Meeting! #SCT2025 #clinicaltrials #PROs Devin Peipert




Excited to share our latest paper calling for a modernized approach to AE measurement, analysis, visualization, & reporting led by Ajay Major, MD, MBA! 📊🧬#hematology #ClinicalTrials #lymsm #dataviz authors.elsevier.com/c/1lAZ98MsWYNW…


As blood cancer treatments evolve, so must the way we track side effects. #PROs are key to understanding tolerability, as explored in our paper led by Vishal Bhatnagar. 🩸Paper series led by Gita Thanarajasingam. #hematology #ClinicalTrials authors.elsevier.com/c/1lAZ98MsWYNW…


Cancer trials with a federal lead sponsor compared to industry sponsor are more likely to investigate de-escalation interventions, rare cancers, and children, among other things using data from clinicaltrials.gov from 2008-2022. #ASCO25 poster by Joe Unger at Fred Hutch Cancer Center.



PROs in the CABINET trial presented by me - cabozantinib for previously-treated advanced neuroendocrine tumors. Side effects & function declined, but HRQOL & overall status improved. Excited for more analysis! #ASCO25 Alliance for Clinical Trials in Oncology




For those missing the #EHA2025 fun, a #podcast discussing the The Lancet Haematology Commission topic of better adverse event assessment was just posted! buzzsprout.com/1564352/episod… Paul Bröckelmann Ajay Major, MD, MBA, Gita Thanarajasingam (also features Vishal Bhatnagar & Lan-Lan Smith not on X)



Listening for the journey home - new The Lancet Haematology podcast featuring a discussion of our commission on adverse events in haematology open.spotify.com/episode/5kT1Ya… #EHA2025


“Enhancing clinicians’ and patients’ ability to read and interpret quality-of-life analyses will support a more complete and critical assessment of the true value of cancer treatments.” Read the Review Article by Massimo Di Maio: eviden.cc/431mUhd #ClinicalTrials
